Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Wright Reports
$75.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ImmunoGen Inc Issues FY 2014 Guidance; Revenue Guidance Above Analysts' Estimates


Friday, 2 Aug 2013 06:30am EDT 

ImmunoGen Inc announced that for fiscal 2014, it expects revenues to be between $66 million and $70 million, net loss to be between $72 million and $76 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $47 million and net income of $(72) million for fiscal 2014. 

Company Quote

10.89
-0.49 -4.31%
24 Jul 2014